NeuroAge Therapeutics is launching Younger 2027, a six-month intervention contest measuring biological age reversal across brain, body, and facial aging markers using clinical-grade epigenetic clocks, cognitive assessment, and functional metrics. The competition provides a structured framework for testing whether specific interventions can measurably reduce biological age within a defined timeframe.
Key Points
- Multi-modal baseline and retest panel measures epigenetic age, cognition, and facial aging
- Ultra tier includes pre-release proteomic clocks, brain MRI, and expanded biomarker panels
- Six-month intervention window with standardized measurement endpoints and $50,000 prize pool
Longevity Analysis
This contest operationalizes a critical gap in longevity research: the ability to measure whether interventions produce measurable biological age reversal in real time. By combining epigenetic clocks across organ systems with cognitive and structural assessments, participants gain actionable feedback on how their specific practices affect aging rate across multiple physiological domains. The emphasis on baseline-to-retest comparison over six months addresses a fundamental challenge in the field—distinguishing genuine biological change from measurement noise—while the diverse measurement panel acknowledges that aging is not unidimensional and that brain, metabolic, and structural changes warrant parallel tracking.
Original published by LifeSpan.io, by Press release.